| Richard Mcaffee, MD | |
|
200 Lothrop St, Pittsburgh, PA 15213-2536 | |
| (412) 647-5909 | |
| Not Available |
| Full Name | Richard Mcaffee |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 19 Years |
| Location | 200 Lothrop St, Pittsburgh, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043538879 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | MD437640 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kaiser Sunnyside Medical Center | Clackamas, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kaiser Foundation Health Plan Of The Northwest | 5799688230 | 1482 |
News Archive
Patients with chronic myeloid leukemia can be treated with tyrosine kinase inhibitors. While these effective drugs lead to deep remission and prolonged survival, primitive leukemia stem cells resist elimination during the remission and persist as a major barrier to cure.
In a study using hypothetical cases, physicians commonly made end-of-life treatment decisions that were not consistent with patient preferences stated in explicit advance directives, according to an article in the July 26 issue of the Archives of Internal Medicine, one of the JAMA/Archives journals.
Wenquan Zou, MD, PhD, an expert in degenerative neurological diseases, along with his collaborators Shu G. Chen, PhD also from the Case Western Reserve University School of Medicine, Jiyan Ma, MD, PhD, from Van Andel Institute in Grand Rapids, Michigan, and Thomas Beach, MD, PhD, from Banner Sun Health Research Institute, Sun City, Arizona, have received a five-year, $3.6 million grant from the National Institutes of Health for diagnosing Parkinson's disease (PD) via an innovative skin testing approach.
TheraQuest Biosciences, Inc., a clinical stage pain management company today unveiled its analgesic product pipeline. TheraQuest also announced the launch of its new corporate website at http://www.theraquestinc.com.
Seattle scientists from Cure First, a non-profit research organization, and SEngine Precision Medicine, a biotech developing targeted, more effective, and less toxic cancer therapeutics, co-authored one of 27 high-profile papers published today by Cell Press.
› Verified 7 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Northwest |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184786527 PECOS PAC ID: 5799688230 Enrollment ID: O20040130000799 |
News Archive
Patients with chronic myeloid leukemia can be treated with tyrosine kinase inhibitors. While these effective drugs lead to deep remission and prolonged survival, primitive leukemia stem cells resist elimination during the remission and persist as a major barrier to cure.
In a study using hypothetical cases, physicians commonly made end-of-life treatment decisions that were not consistent with patient preferences stated in explicit advance directives, according to an article in the July 26 issue of the Archives of Internal Medicine, one of the JAMA/Archives journals.
Wenquan Zou, MD, PhD, an expert in degenerative neurological diseases, along with his collaborators Shu G. Chen, PhD also from the Case Western Reserve University School of Medicine, Jiyan Ma, MD, PhD, from Van Andel Institute in Grand Rapids, Michigan, and Thomas Beach, MD, PhD, from Banner Sun Health Research Institute, Sun City, Arizona, have received a five-year, $3.6 million grant from the National Institutes of Health for diagnosing Parkinson's disease (PD) via an innovative skin testing approach.
TheraQuest Biosciences, Inc., a clinical stage pain management company today unveiled its analgesic product pipeline. TheraQuest also announced the launch of its new corporate website at http://www.theraquestinc.com.
Seattle scientists from Cure First, a non-profit research organization, and SEngine Precision Medicine, a biotech developing targeted, more effective, and less toxic cancer therapeutics, co-authored one of 27 high-profile papers published today by Cell Press.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Richard Mcaffee, MD 200 Lothrop St, Forbes Tower, Suite 9055, Pittsburgh, PA 15213-2536 Ph: () - | Richard Mcaffee, MD 200 Lothrop St, Pittsburgh, PA 15213-2536 Ph: (412) 647-5909 |
News Archive
Patients with chronic myeloid leukemia can be treated with tyrosine kinase inhibitors. While these effective drugs lead to deep remission and prolonged survival, primitive leukemia stem cells resist elimination during the remission and persist as a major barrier to cure.
In a study using hypothetical cases, physicians commonly made end-of-life treatment decisions that were not consistent with patient preferences stated in explicit advance directives, according to an article in the July 26 issue of the Archives of Internal Medicine, one of the JAMA/Archives journals.
Wenquan Zou, MD, PhD, an expert in degenerative neurological diseases, along with his collaborators Shu G. Chen, PhD also from the Case Western Reserve University School of Medicine, Jiyan Ma, MD, PhD, from Van Andel Institute in Grand Rapids, Michigan, and Thomas Beach, MD, PhD, from Banner Sun Health Research Institute, Sun City, Arizona, have received a five-year, $3.6 million grant from the National Institutes of Health for diagnosing Parkinson's disease (PD) via an innovative skin testing approach.
TheraQuest Biosciences, Inc., a clinical stage pain management company today unveiled its analgesic product pipeline. TheraQuest also announced the launch of its new corporate website at http://www.theraquestinc.com.
Seattle scientists from Cure First, a non-profit research organization, and SEngine Precision Medicine, a biotech developing targeted, more effective, and less toxic cancer therapeutics, co-authored one of 27 high-profile papers published today by Cell Press.
› Verified 7 days ago
Dr. Eric Lowell Davidson, M.D. Anesthesiology Medicare: May Accept Medicare Assignments Practice Location: 3550 Terrace Street, Dept. Of Ccm, University Of Pittsburgh, Pittsburgh, PA 15261 Phone: 412-647-3136 | |
Dr. Ashima Dhamija, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 320 East North Avenue, Pittsburgh, PA 15212 Phone: 412-359-6581 Fax: 412-359-3483 | |
Michelle Masnovi, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: Upmc Department Of Anesthesiology, 3471 Fifth Avenue Kaufmann Bldg Suite 402, Pittsburgh, PA 15213 Phone: 412-692-4572 | |
Sruthi Rangu, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 320 E North Ave, Pittsburgh, PA 15212 Phone: 412-359-3166 | |
Igor Semenov, Anesthesiology Medicare: Medicare Enrolled Practice Location: 3705 5th Ave, One Children's Hospital Drive, Pittsburgh, PA 15213 Phone: 412-692-5260 | |
Susan Mcelroy, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4727 Friendship Ave, #240, Pittsburgh, PA 15224 Phone: 412-235-5870 | |
Joseph Talarico, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 200 Lothrop St, Pittsburgh, PA 15213 Phone: 412-647-3260 |